States with medical marijuana laws saw 20 percent drop in some opioid prescriptions
States with active medical marijuana laws saw certain opioid prescription rates drop nearly 20 percent compared to states without medical marijuana programs, according to a first-of-its-kind study out of Columbia University’s Irving Medical Center.
Authors said the findings underscore the importance of providing patients with pain management alternatives, such as cannabis, in efforts to reduce opioid use.
Stories you may be interested in
DeSantis OKs telehealth for Florida medical marijuana patients
TAMPA, Fla. (WFLA) — Florida Gov. Ron DeSantis signed a bill allowing the state’s 828,000 medical marijuana patients to use telehealth to visit their doctors. On Monday, DeSantis signed HB-387, titled “Medical Use of Marijuana,” which allows patients renewing their medical marijuana recommendation to meet with their doctors online. Currently, patients must visit their doctor in person…
Read More 
More Treatment Options, Better Patient Outcomes
As more states start to pass medical marijuana legislation, patients benefit from having more options available to them regarding their treatment. In fact, a recent study from Columbia University’s Irving Medical Center found that, “States with active medical marijuana laws saw certain opioid prescription rates drop nearly 20 percent compared to states without medical marijuana…
Read More 
CEO Spotlight: James West
As a former academic coordinator for the City University of New York Research Foundation and Medgar Evers College, CEO and co-founder of Arfinn Med, James West, has extensive experience in adult education and professional training programming. James put this extensive education to good use when he noticed that there was a direct need for a…
Read More 
Customize Your Patient Notes with Arfinn Med
Joining the text messaging update, the Arfinn Med portal now presents the ability to create note taking templates. This innovative addition will allow physicians to streamline the data and information that they are collecting from patients, resulting in their cases staying aligned and concise. Additionally, through this function, physicians will be able to pick and…
Read More 
Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease
A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More 
European Parliament Passes Cannabis Resolution, Joins WHO In Supporting Medical Marijuana
Following reports about the World Health Organization (WHO) recommending a rescheduling of cannabis and several of its key components under international drug treaties, the European Parliament voted on Wednesday on a resolution that would help advance medical cannabis in the countries that form the European Union. Read the full story here.
Read More